“These ATLL tumors secrete proteins that also cause the bones in these patients to weaken and resorb,” explained Thomas Rosol, professor of veterinary biosciences and dean of the College of Veterinary Medicine at Ohio State University.

“When that happens, the amount of calcium in the blood can build up to toxic levels.” So killing the cancer cells in these patients is only half the battle, he says. “We have to stop the resorption of bone and the release of calcium that the cancer causes.”

Earlier tissue culture studies on a new anticancer drug, PS-341, showed promise in attacking the cancer cells but before now, an effective animal model wasn't available for researchers to use that included HHM's calcium buildup.

Rosol and his team turned to a combination of PS-341 and zoledronic acid, a form of bisphosphonate that is widely used now to combat the bone loss of osteoporosis and other diseases.

They would then test the two drugs, separately and combined, in a group of specialized mice that had been injected with ATLL tumor cells.

“We can inject these tumor cells into the abdomen of the mice and they will grow in the animals' lymph nodes,” explained Rosol, “but normally, you can't detect the extent of the animal's disease until the cancer is in its later stages.”

To solve this, Rosol's team took a novel approach:

They took a gene responsible for a firefly's glow and genetically inserted it into these tumor cells. That gene produces the enzyme luciferase in the insects which, when combined with another compound, luciferin, causes the firefly's distinctive glow.

The mice then received these genetically modified tumor cells and the researchers injected luciferin into the animals. Cancer cells containing the luciferase would combine with the luciferin and glow in the dark, giving the team a clear picture of the extent of disease inside the animal.

“We put these mice inside a blackened chamber with a digital camera and then took their pictures. The only light present would be the light emitted by the cancer cells,” Rosol said.

“We just measured the light that we could see coming out of the animal – the more light, the more tumor growth; the less light, less tumor.”

He said that with the tumor cells emitting light, his team was able to gauge the volume of tumor cells in the animal's body. “It is amazingly sensitive and precise, letting us see to a level of only a few hundred cells,” he said. “That gives us a good method for monitoring the tumor cells.”

So when the researchers tested the effects of the two drugs, they found that the zoledronic acid halted the bone resorption, reducing the harmful calcium in the body, and that the anticancer drug PS-341 killed more than 95 percent of the ATLL cells.

“It was very effective against ATLL, eliminating almost all of the tumor cells,” Rosol said.

What they didn't expect was that in some mice treated only with the zoledronic acid and not with the PS-341 anticancer drug, the zoledronic acid reduced some of the cancer growth as well.

“We have no idea why some animals responded in this way while others didn't,” Rosol said, “but the next step may be to try to understand the processes involved in how the tumor cells cause the resorption of the bones and the release of calcium.

“Hopefully, we'll soon see this work tested in human clinical trials and that perhaps will lead to a treatment for this disease.”

The research was supported in part by the National Cancer Institute and the National Center for Research Resources. Working with Rosol on the project were Sherry Shu, Murali Nadella, Nanda Thudi and Jillian Werbeck, all doctoral students; research scientist Wessel Dirksen, statistician Soledad Fernandez, and Michael Lairmore, professor and chair of veterinary biosciences.

#

Contact: Thomas Rosol, (614) 688-8749; Thomas.Rosol@cvm.osu.edu

Written by Earle Holland, (614) 292-8384; Holland.8@osu.edu